Skip to main content
Livermore
Livermore
ZHEN

Eventide Asset Management, LLC

SEC CIK
0001442891
Latest filing
Aug 14, 2026

The latest 13F from Eventide Asset Management, LLC covers Q2 2026 (filed Aug 14, 2026): 301 long positions worth $7.48B. The top 10 holdings make up 23.8% of the portfolio, and the largest is Guardant Health, Inc. (GH) at 3.9%. Livermore has 23 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
60
Est. +$289.0M
Added
159
Est. +$440.9M
Reduced
69
Est. −$560.3M
Sold out
37
Est. −$254.1M

Top 5 holdings

Share of this quarter's portfolio value

  1. GHGuardant Health, Inc.
    3.9%$293.8MHistory
  2. LRCXLam Research Corp
    3.9%$291.7MHistory
  3. XMTRXometry, Inc.
    2.8%$208.4MHistory
  4. TTTrane Technologies plc
    2.7%$203.5MHistory
  5. MIRMMirum Pharmaceuticals, Inc.
    2.0%$146.2MHistory

Share of portfolio

Top 5 holdings and the other 296 positions, by share of portfolio value

  1. GH3.9%
  2. LRCX3.9%
  3. XMTR2.8%
  4. TT2.7%
  5. MIRM2.0%
  6. Other 296 positions84.7%

Biggest buys

New and added positions, by estimated amount bought

  1. AVLNAvalyn Pharma Inc.
    +$45.3MNewHistory
  2. DELLDell Technologies Inc.
    +$37.8MAddedHistory
  3. CDNSCadence Design Systems Inc
    +$31.6MAddedHistory
  4. RELYRemitly Global, Inc.
    +$29.9MNewHistory
  5. FITBFifth Third Bancorp
    +$28.2MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. DELLDell Technologies Inc.
    +0.80 pp0.3% → 1.1%History
  2. DDOGDatadog, Inc.
    +0.72 pp0.5% → 1.2%History
  3. AVLNAvalyn Pharma Inc.
    +0.61 pp0.0% → 0.6%History
  4. CDNSCadence Design Systems Inc
    +0.43 pp0.1% → 0.5%History
  5. RELYRemitly Global, Inc.
    +0.40 pp0.0% → 0.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. XMTRXometry, Inc.
    −$78.3MReducedHistory
  2. GHGuardant Health, Inc.
    −$60.7MReducedHistory
  3. PLDPrologis, Inc.
    −$56.1MSold outHistory
  4. AXSMAxsome Therapeutics, Inc.
    −$49.6MReducedHistory
  5. APGEApogee Therapeutics, Inc.
    −$39.5MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. PLDPrologis, Inc.
    −0.93 pp0.9% → 0.0%History
  2. GLBEGlobal-E Online Ltd.
    −0.62 pp0.6% → 0.0%History
  3. ROPRoper Technologies Inc
    −0.54 pp0.6% → <0.1%History
  4. WCNWaste Connections, Inc.
    −0.49 pp0.8% → 0.3%History
  5. CNTACentessa Pharmaceuticals plc
    −0.44 pp0.4% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$7.48B
+$1.44B (+23.8%) vs. prior quarter
Positions
301
+23 vs. prior quarter
Top 10 concentration
23.8%
Top 10 as share of value
Turnover
10.8%
Q2 2026, one quarter
Average holding period
11.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $7.83B (Q4 2021)

Q1 2021: $6.75BQ2 2021: $7.44BQ3 2021: $7.56BQ4 2021: $7.83BQ1 2022: $6.38BQ2 2022: $4.68BQ3 2022: $5.08BQ4 2022: $5.07BQ1 2023: $5.45BQ2 2023: $5.92BQ3 2023: $5.55BQ4 2023: $6.13BQ1 2024: $6.37BQ2 2024: $5.84BQ3 2024: $5.80BQ4 2024: $5.49BQ1 2025: $5.02BQ2 2025: $5.71BQ3 2025: $6.08BQ4 2025: $6.40BQ1 2026: $6.05BQ2 2026: $7.48B
Q1 2021Q2 2026
13F filings of Eventide Asset Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 2026301$7.48BGHLRCXXMTRvs. Q1 2026SEC
Q1 2026May 15, 2026278$6.05BGHTTLRCXvs. Q4 2025SEC
Q4 2025Feb 13, 2026268$6.40BGHXMTRMIRMvs. Q3 2025SEC
Q3 2025Nov 14, 2025240$6.08BGHMIRMXMTRvs. Q2 2025SEC
Q2 2025Aug 14, 2025237$5.71BVRNAGHTTvs. Q1 2025SEC
Q1 2025May 15, 2025217$5.02BVRNAGHTTvs. Q4 2024SEC
Q4 2024Feb 14, 2025204$5.49BVRNATTXMTRvs. Q3 2024SEC
Q3 2024Nov 14, 2024180$5.80BTTDHIODFLvs. Q2 2024SEC
Q2 2024Aug 13, 2024160$5.84BTTTMDXWCNvs. Q1 2024SEC
Q1 2024May 15, 2024156$6.37BTTZNTLSWAVvs. Q4 2023SEC
Q4 2023Feb 20, 2024Amended152$6.13BXMTRTTZNTLvs. Q3 2023SEC
Q3 2023Nov 14, 2023155$5.55BODFLTTARGXvs. Q2 2023SEC
Q2 2023Aug 15, 2023139$5.92BZNTLPANWEXASvs. Q1 2023SEC
Q1 2023May 15, 2023148$5.45BMTDPANWDOCSvs. Q4 2022SEC
Q4 2022Feb 13, 2023143$5.07BMTDDOCSTTvs. Q3 2022SEC
Q3 2022Nov 14, 2022138$5.08BRXDXMTDASNDvs. Q2 2022SEC
Q2 2022Aug 15, 2022136$4.68BBHVNMTDARGXvs. Q1 2022SEC
Q1 2022May 16, 2022136$6.38BBHVNMTDASNDvs. Q4 2021SEC
Q4 2021Feb 14, 2022146$7.83BASNDBHVNMTDvs. Q3 2021SEC
Q3 2021Nov 15, 2021151$7.56BASNDFIVNCRWDvs. Q2 2021SEC
Q2 2021Aug 16, 2021152$7.44BCRWDASNDFIVNvs. Q1 2021SEC
Q1 2021May 14, 2021155$6.75BEXASASNDFIVN–SEC

13D and 13G filings

Companies where Eventide Asset Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

3 companies, largest stake first.

Companies where Eventide Asset Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
BBNXBeta Bionics, Inc.13G/A13.40%5.95M shares+2.08 ppfrom 11.32%Feb 5, 20252 filingsMay 15, 2026SEC
OVIDOvid Therapeutics Inc.13G/A6.30%11.8M shares−1.00 ppfrom 7.30%May 15, 20262 filingsAug 14, 2026SEC
IMMXImmix Biopharma, Inc.13G5.60%3.89M sharesNewAug 14, 20261 filingAug 14, 2026SEC

Latest filings

102 filings on file made by Eventide Asset Management, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Eventide Asset Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
OVIDOvid Therapeutics Inc.Aug 14, 202611:41 AM ET13G/A6.30%11.8M shares−1.00 ppfrom 7.30%Jun 30, 2026SEC
IMMXImmix Biopharma, Inc.Aug 14, 202611:36 AM ET13G5.60%3.89M sharesNewJun 30, 2026SEC
XMTRXometry, Inc.Aug 14, 202611:28 AM ET13G/A4.00%2.15M shares−2.72 ppfrom 6.72%Below 5%Jun 30, 2026SEC
OVIDOvid Therapeutics Inc.May 15, 202611:57 AM ET13G7.30%12.8M sharesNewMar 31, 2026SEC
BBNXBeta Bionics, Inc.May 15, 202611:45 AM ET13G/A13.40%5.95M shares+2.08 ppfrom 11.32%Mar 31, 2026SEC
COLLCollegium Pharmaceutical, IncMay 15, 202611:33 AM ET13G/A4.50%1.42M shares−1.40 ppfrom 5.90%Below 5%Mar 31, 2026SEC
IVAInventiva S.A.Feb 13, 20261:36 PM ET13G/A4.60%9.37M shares−2.10 ppfrom 6.70%Below 5%Dec 31, 2025SEC
EVHEvolent Health, Inc.Feb 13, 20261:22 PM ET13G/A0.00%1.71K shares−5.40 ppfrom 5.40%Below 5%Dec 31, 2025SEC
MIRMMirum Pharmaceuticals, Inc.Feb 13, 20261:09 PM ET13G/A4.10%2.09M shares−1.33 ppfrom 5.43%Below 5%Dec 31, 2025SEC
COLLCollegium Pharmaceutical, IncFeb 13, 202612:51 PM ET13G/A5.90%1.88M shares–Dec 31, 2025SEC
EVHEvolent Health, Inc.Nov 14, 20253:37 PM ET13G/A5.40%6.29M shares+1.90 ppfrom 3.50%Sep 30, 2025SEC
YARWYarrow Bioscience, Inc.Nov 14, 20253:23 PM ET13G/A0.00%0 shares−9.99 ppfrom 9.99%Below 5%Sep 30, 2025SEC
YARWYarrow Bioscience, Inc.Aug 14, 20254:49 PM ET13G/A9.99%1.85M shares–Jun 30, 2025SEC
EVHEvolent Health, Inc.Aug 14, 20253:07 PM ET13G/A3.50%4.09M shares−1.70 ppfrom 5.20%Below 5%Jun 30, 2025SEC
CLDXCelldex Therapeutics, Inc.Aug 14, 20252:59 PM ET13G/A2.00%1.36M shares–Below 5%Jun 30, 2025SEC
IVAInventiva S.A.May 15, 20254:45 PM ET13G6.70%10.1M sharesNewMay 9, 2025SEC
EVHEvolent Health, Inc.May 14, 20254:04 PM ET13G5.20%6.08M sharesNewMar 31, 2025SEC
ZNTLZentalis Pharmaceuticals, Inc.May 14, 20253:51 PM ET13G/A0.00%0 shares0.00 ppfrom 0.00%Below 5%Mar 31, 2025SEC
AURAAura Biosciences, Inc.May 14, 20253:28 PM ET13G/A0.00%0 shares0.00 ppfrom 0.00%Below 5%Mar 31, 2025SEC
ZNTLZentalis Pharmaceuticals, Inc.May 13, 20255:30 PM ET13G/A0.00%0 shares−6.28 ppfrom 6.28%Below 5%Mar 31, 2025SEC